Nucleic Acid-based Therapeutics Market 2026: Scaling to $93.4B by 2032. > Your story

• List
• Write
• 게시판 리스트 옵션
  • Modity
  • Delete

Nucleic Acid-based Therapeutics Market Size:

Nucleic Acid-based Therapeutics Market size is estimated to reach over USD 15,260.97 Million by 2031 from a value of USD 5,530.55 Million in 2023 and is projected to grow by USD 6,180.17 Million in 2024, growing at a CAGR of 13.5% from 2024 to 2031.

mRNA Beyond COVID-19

• In 2026, mRNA technology is being pivoted toward personalized oncology vaccines and rare genetic disorders.
• The platform’s "programmable" nature allows for rapid clinical trials for seasonal respiratory viruses.

Nucleic Acid-based Therapeutics Market Scope

The nucleic acid-based therapeutics are therapies that utilize nucleic acids such as DNA, RNA, and oligonucleotides to modulate gene expression and treat various diseases at the molecular level. These therapeutics include RNA interference (RNAi), antisense oligonucleotides, aptamers, and gene therapies designed to target the root cause of genetic and acquired diseases. Key characteristics include high specificity, the ability to silence disease-causing genes, and potential applications across a broad range of therapeutic areas. The benefits of these therapeutics include precise targeting of disease pathways, reduced off-target effects, and promising outcomes for conditions previously considered untreatable. Applications cover genetic disorders, cancer, infectious diseases, and cardiovascular conditions. End-users include pharmaceutical and biotechnology companies, research institutes, and healthcare providers, driven by advancements in genomic technologies, increasing prevalence of chronic diseases, and rising investments in personalized medicine.

Regulatory Maturation in the Nucleic Acid-based Therapeutics Market

• The Nucleic Acid-based Therapeutics Market is benefiting from new FDA "Fast Track" designations for oligonucleotide drugs.
• International standardization of manufacturing CMC (Chemistry, Manufacturing, and Controls) is stabilizing the Nucleic Acid-based Therapeutics Market.
• Gene-silencing drugs (siRNA) are emerging as the highest-growth segment within the Nucleic Acid-based Therapeutics Market.

Rise of RNA Interference (RNAi)

• RNAi therapies are proving highly effective in managing chronic liver diseases and hypertension.
• Long-acting RNAi formulations now allow for bi-annual or even annual dosing, increasing patient compliance.

Genome Editing and CRISPR Integration

• In-vivo CRISPR treatments are moving into Phase III trials for sickle cell and TTR amyloidosis.
• The market is shifting from "ex-vivo" (cell-based) to direct injection of nucleic acid editing tools.

Recent Industry Developments

• In December 2023, the FDA approved Casgevy, the first CRISPR-based therapy, for treating sickle cell disease and transfusion-dependent beta-thalassemia. This therapy edits patients' hematopoietic stem cells to produce higher levels of fetal hemoglobin, reducing disease symptoms.

Decentralized "Factory-in-a-Box" Manufacturing

• Modular manufacturing units are allowing for localized production of personalized nucleic acid drugs.
• This reduces cold-chain logistics costs, which traditionally account for 15% of the drug’s price.

Antisense Oligonucleotides (ASOs) for Rare Diseases

• ASOs are providing the first viable treatments for previously "undruggable" pediatric neurodegenerative conditions.
• The "N-of-1" personalized medicine model is gaining traction in specialized research hospitals.

Market Restraint: High Treatment Costs

• Individual gene therapies can cost upwards of $2 million, leading to significant insurance and payer friction.
• Equitable access to these "frontier" medicines remains a major political and ethical challenge in 2026.

Precision Delivery via Lipid Nanoparticles (LNPs)

• Advancements in LNP chemistry are allowing for "organ-specific" targeting, reducing systemic side effects.
• Extra-hepatic delivery (targeting the lungs, brain, and heart) is the primary R&D focus for 2026.

Future Outlook: The "Digital Drug" Era

• By 2032, the market is expected to reach $93.46 billion as nucleic acids become the third pillar of pharmacology.
• AI-designed sequences will allow for "Same-Day" therapeutic design once a patient's genome is sequenced.

About Us:
At Consegic Business Intelligence Pvt. Ltd., we empower businesses with actionable insights and innovative market intelligence solutions. Our tailored research and data-driven strategies help organizations navigate complex industry landscapes and make confident decisions.
Specializing in market research, consulting, and competitive analysis, we deliver precise and holistic insights across global and regional markets. Our client-focused approach ensures customized solutions that drive growth and foster informed decision-making.
Contact Us:
Consegic Business intelligence Pvt Ltd.
Contact No: +1-252-552-1404
Email: [email protected]